Annunziata Nusca

Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention

Vincenzo Pasceri, Giuseppe Patti, Annunziata Nusca et al. · Circulation · 2004 · 465 citations

Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention

Giuseppe Patti, Annunziata Nusca, Fabio Mangiacapra et al. · Journal of the American College of Cardiology · 2008 · 350 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +9

Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty–Contrast-Induced Nephropathy] Trial

Giuseppe Patti, Elisabetta Ricottini, Annunziata Nusca et al. · The American Journal of Cardiology · 2011 · 187 citations

Percutaneous Coronary Intervention, Contrast-induced Nephropathy, Cardiovascular Disease +12

Usefulness of Statin Pretreatment to Prevent Contrast-Induced Nephropathy and to Improve Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention

Giuseppe Patti, Annunziata Nusca, Massimo Chello et al. · The American Journal of Cardiology · 2007 · 140 citations

Percutaneous Coronary Intervention, Contrast-induced Nephropathy, Cardiovascular Disease +12

Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention

Giuseppe Patti, Massimo Chello, Vincenzo Pasceri et al. · Journal of the American College of Cardiology · 2006 · 122 citations

Percutaneous Coronary Intervention, Cardiovascular Disease, Pharmacology +9